Literature DB >> 12651881

Cholestasis.

R Oude Elferink1.   

Abstract

In contrast with urine formation, bile flow is not dependent on hydrostatic forces, but driven by osmotic pressure of solutes secreted across the apical membrane of hepatocytes and bile duct epithelial cells. This secretory process is mediated by a set of primary active transporters that use ATP hydrolysis to pump solutes against the concentration gradient. The most important solutes in bile are bile salts, lipids, electrolytes, and organic anions. The direct consequence of the osmotic mechanism of bile formation is that impaired function of these pumps leads to impaired bile flow-that is, cholestasis. The function of these pumps is highlighted by a number of inherited cholestatic diseases, which are caused by mutations in these genes. Identification of the molecular defect in these diseases was not only important for diagnostic reasons but also emphasised that impaired transporter function has pathological consequences. Indeed, it is now becoming clear that impaired or downregulated transporter function is also involved in the pathogenesis of acquired cholestatic syndromes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12651881      PMCID: PMC1867745          DOI: 10.1136/gut.52.suppl_2.ii42

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  106 in total

1.  A multidrug resistance transporter from human MCF-7 breast cancer cells.

Authors:  L A Doyle; W Yang; L V Abruzzo; T Krogmann; Y Gao; A K Rishi; D D Ross
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

2.  Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane.

Authors:  J König; D Rost; Y Cui; D Keppler
Journal:  Hepatology       Date:  1999-04       Impact factor: 17.425

3.  MRP3, an organic anion transporter able to transport anti-cancer drugs.

Authors:  M Kool; M van der Linden; M de Haas; G L Scheffer; J M de Vree; A J Smith; G Jansen; G J Peters; N Ponne; R J Scheper; R P Elferink; F Baas; P Borst
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

4.  Identification of a nuclear receptor for bile acids.

Authors:  M Makishima; A Y Okamoto; J J Repa; H Tu; R M Learned; A Luk; M V Hull; K D Lustig; D J Mangelsdorf; B Shan
Journal:  Science       Date:  1999-05-21       Impact factor: 47.728

5.  Bile acids: natural ligands for an orphan nuclear receptor.

Authors:  D J Parks; S G Blanchard; R K Bledsoe; G Chandra; T G Consler; S A Kliewer; J B Stimmel; T M Willson; A M Zavacki; D D Moore; J M Lehmann
Journal:  Science       Date:  1999-05-21       Impact factor: 47.728

Review 6.  Recent progress in P-glycoprotein research.

Authors:  K Ueda; A Yoshida; T Amachi
Journal:  Anticancer Drug Des       Date:  1999-04

7.  Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3).

Authors:  T Hirohashi; H Suzuki; Y Sugiyama
Journal:  J Biol Chem       Date:  1999-05-21       Impact factor: 5.157

8.  Treatment of progressive familial intrahepatic cholestasis: liver transplantation or partial external biliary diversion.

Authors:  H Ismail; P Kaliciński; M Markiewicz; I Jankowska; J Pawłowska; P Kluge; E Eliadou; A Kamiński; M Szymczak; T Drewniak; Y Revillon
Journal:  Pediatr Transplant       Date:  1999-08

9.  Up-regulation of the multidrug resistance genes, Mrp1 and Mdr1b, and down-regulation of the organic anion transporter, Mrp2, and the bile salt transporter, Spgp, in endotoxemic rat liver.

Authors:  T A Vos; G J Hooiveld; H Koning; S Childs; D K Meijer; H Moshage; P L Jansen; M Müller
Journal:  Hepatology       Date:  1998-12       Impact factor: 17.425

10.  Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione.

Authors:  D W Loe; R G Deeley; S P Cole
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

View more
  8 in total

Review 1.  Immunology of hepatic diseases during pregnancy.

Authors:  Lars Bremer; Christoph Schramm; Gisa Tiegs
Journal:  Semin Immunopathol       Date:  2016-06-20       Impact factor: 9.623

2.  Intrahepatic cholestasis as a paraneoplastic syndrome associated with pheochromocytoma.

Authors:  C H Chung; C H Wang; C Y Tzen; C P Liu
Journal:  J Endocrinol Invest       Date:  2005-02       Impact factor: 4.256

Review 3.  The bile salt export pump: molecular properties, function and regulation.

Authors:  Marco Arrese; Meenakshisundaram Ananthanarayanan
Journal:  Pflugers Arch       Date:  2004-07-24       Impact factor: 3.657

4.  Biliary secretion of fluid phase markers is modified under post-cholestatic conditions.

Authors:  Isabella Ellinger; Renate Fuchs
Journal:  Wien Med Wochenschr       Date:  2008

5.  Protective effects of ursodeoxycholic acid on chenodeoxycholic acid-induced liver injury in hamsters.

Authors:  Tomomichi Iwaki; Kaoru Ishizaki; Shuji Kinoshita; Hideki Tanaka; Atsushi Fukunari; Makoto Tsurufuji; Teruaki Imada
Journal:  World J Gastroenterol       Date:  2007-10-07       Impact factor: 5.742

6.  Bile secretory function in the obese Zucker rat: evidence of cholestasis and altered canalicular transport function.

Authors:  M Pizarro; N Balasubramaniyan; N Solís; A Solar; I Duarte; J F Miquel; F J Suchy; M Trauner; L Accatino; M Ananthanarayanan; M Arrese
Journal:  Gut       Date:  2004-12       Impact factor: 23.059

7.  Danning tablets attenuates α-naphthylisothiocyanate-induced cholestasis by modulating the expression of transporters and metabolic enzymes.

Authors:  Lili Ding; Binfeng Zhang; Changsen Zhan; Li Yang; Zhengtao Wang
Journal:  BMC Complement Altern Med       Date:  2014-07-17       Impact factor: 3.659

8.  Bile Acid Dysregulation Is Intrinsically Related to Cachexia in Tumor-Bearing Mice.

Authors:  Morgane M Thibaut; Justine Gillard; Adeline Dolly; Martin Roumain; Isabelle A Leclercq; Nathalie M Delzenne; Giulio G Muccioli; Laure B Bindels
Journal:  Cancers (Basel)       Date:  2021-12-20       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.